AP NEWS

$3.1 Bn Sickle Cell Disease Market Insights, Epidemiology and Market Forecast 2017-2025 - ResearchAndMarkets.com

September 11, 2018

DUBLIN--(BUSINESS WIRE)--Sep 11, 2018--The “Sickle Cell Disease - Market Insights, Epidemiology and Market Forecast - 2025” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The therapeutic market of Sickle Cell Disease in 6MM is expected to reach USD 3.1 Billion in 2025.Sickle Cell Disease (SCD) - Market Insights, Epidemiology and Market Forecast-2025 provides an overview of Sickle Cell Disease, epidemiology and market trends of the Sickle Cell Disease for the United States and EU5 (Germany, Spain, Italy, France and United Kingdom). The report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Sickle Cell Disease from 2017 to 2025 segmented by seven major markets. In addition, the report also includes the forecasted epidemiology of Sickle Cell Disease till 2025. The report also covers market drivers, market barriers and unmet medical need.

Greater uptake by the three emerging novel drugs Endari (Emmaus Lifesciences), GBT-440 (GBT Therapeutics), and Crizanlizumab (Novartis) will primarily drive the SCD market. As the number of effective treatments for the Sickle Cell Disease increase in the market during the forecast period, the prescription medications (HU; Iron Chelators, Analegesics, Antibiotics, vaccines) market share will start to decrease. Emmaus’s Endari will be the preferred therapy for the complications associated with SCD owing to its less cost, which will give more patient access to this therapy.

United States contributes the major share of Sickle Cell Disease market as compared to EU5 countries.

Key Topics Covered:

1. Report Summary

2. Sickle Cell Disease Market Overview at a Glance

3. Disease Background and Overview: Sickle Cell Disease

4. Epidemiology and Patient Population

5. Prevalent Population of Sickle Cell Disease in 6MM

6. Epidemiology of Sickle Cell Disease

7. United States

8. Germany

9. France

10. Spain

11. Italy

12. United Kingdom

13. Japan

14. Treatment Practices

15. Specific pain management

16. Supportive care: Oxygen therapy

17. Hydration: Fluid replacement

18. Antibiotics

19. Transfusions

20. First line treatment

21. Hydroxyurea

22. Bone marrow transplantation

23. Current Unmet needs

24. Marketed Drugs for Sickle Cell Disease

25. Emerging Drugs for Sickle Cell Disease

26. Failed Therapies

27. Sickle Cell Disease (SCD): Market Analysis

28. United States

29. Europe

30. Germany

31. France

32. Italy

33. Spain

34. United Kingdom

Companies Mentioned

Global Blood Therapeutics, Inc.Pfizer Inc.Novartis PharmaceuticalsEmmaus Life Sciences, Inc.Bristol-Myers SquibbFor more information about this drug pipelines report visit https://www.researchandmarkets.com/research/ll7q8d/3_1_bn_sickle?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180911005402/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Hematological Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH GENETICS PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/11/2018 07:17 AM/DISC: 09/11/2018 07:17 AM

http://www.businesswire.com/news/home/20180911005402/en

AP RADIO
Update hourly